suzetrigine
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pain, Acute Postoperative
Conditions
Pain, Acute Postoperative, Breast Disease
Trial Timeline
Mar 30, 2026 → Sep 30, 2027
NCT ID
NCT07463430About suzetrigine
suzetrigine is a approved stage product being developed by Vertex Pharmaceuticals for Pain, Acute Postoperative. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07463430. Target conditions include Pain, Acute Postoperative, Breast Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07463430 | Approved | Recruiting |
| NCT07378865 | Phase 1 | Recruiting |
| NCT06887959 | Approved | Completed |
| NCT06887972 | Approved | Completed |
| NCT06696443 | Phase 3 | Active |
| NCT05661734 | Phase 3 | Completed |
Competing Products
20 competing products in Pain, Acute Postoperative